MedPage Today December 6, 2024
Rachael Robertson

— Physicians, policymakers raise questions about LillyDirect connecting patients with telehealth

This story is part of a series called “Ozempic: Weighing the Risks and Benefits.” It was produced in part through a grant from the NIHCM Foundation.

Just a few months after Eli Lilly’s tirzepatide (Zepbound) was approved to treat obesity, the pharmaceutical company in January 2024 launched LillyDirect, a digital health platform for patients with obesity, diabetes, and migraine.

Pfizer — which is developing a once-daily weight-loss pill — followed this summer with PfizerForAll, a digital health platform for patients with migraine.

Both offer a connection with doctors right from their home page, albeit through third-party telehealth companies. These are the first two examples of pharmaceutical companies making quicker...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma, Pharma / Biotech
Mark Cuban: A Master Disrupter for American Healthcare
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
What's next for Amazon in healthcare?
How has U.S. Spending on Health Care Changed Over Time?
Merck enters $2B licensing deal for weight loss drug

Share This Article